Can a prolonged QT interval cause chest pain?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Prolonged QT interval can indeed cause chest pain, often manifesting as sharp, stabbing, or squeezing sensations in the chest, typically associated with torsades de pointes, a life-threatening arrhythmia that can occur in individuals with QT intervals exceeding 500 milliseconds 1.

Causes of Prolonged QT Interval

  • Certain medications, such as sotalol and quinidine, can precipitate QT prolongation and subsequent chest pain, particularly when used in conjunction with other QT-prolonging agents or in patients with underlying cardiac conditions 1.
  • Anticancer therapies, including arsenic trioxide, histone deacetylase inhibitors, and tyrosine kinase inhibitors, can also prolong the QT interval and increase the risk of torsades de pointes 1.

Management of Prolonged QT Interval

  • Monitoring of the QTc interval is crucial in patients with long QT syndrome, and QT-prolonging medications should be avoided unless there is no suitable alternative 1.
  • Maintaining normal potassium and magnesium balance is essential to prevent hypokalemia and hypomagnesaemia, which can precipitate torsades de pointes 1.
  • Electrolyte imbalances should be promptly corrected before initiating therapy, and electrocardiograms (ECGs) should be monitored periodically for QT prolongation and arrhythmia 1.

From the FDA Drug Label

In an unblinded multicenter trial of 25 patients with SVT and/or VT receiving daily doses of 30,90 and 210 mg/m2 with dosing every 8 hours for a total of 9 doses, no Torsades de Pointes or other serious new arrhythmias were observed. One (1) patient, receiving 30 mg/m2 daily, was discontinued because of increased frequency of sinus pauses/bradycardia Additional cardiovascular AEs were seen at the 90 and 210 mg/m2 daily dose levels. They included QT prolongations (2 patients), sinus pauses/bradycardia (1 patient), increased severity of atrial flutter and reported chest pain (1 patient).

A prolonged QT interval may be associated with chest pain, as one patient in a clinical trial reported chest pain in addition to QT prolongation and other cardiovascular adverse events 2. However, the label does not establish a direct causal relationship between QT interval prolongation and chest pain.

From the Research

Prolonged QT Interval and Chest Pain

  • There is no direct evidence in the provided studies that links a prolonged QT interval to chest pain as a symptom.
  • However, the studies suggest that a prolonged QT interval can lead to life-threatening arrhythmias such as Torsades de Pointes (TdP) 3, 4, 5, 6, 7.
  • TdP can cause symptoms such as dizziness, syncope, and palpitations, but chest pain is not typically mentioned as a symptom 7.
  • The management of TdP or marked QT prolongation includes removal or correction of precipitants, including discontinuation of culprit drugs and institution of cardiac monitoring, as well as correction of electrolyte abnormalities and hypoxia 7.
  • In some cases, TdP can progress to ventricular fibrillation and sudden death, which may be preceded by symptoms such as chest pain, but this is not explicitly stated in the studies 4, 7.

Risk Factors for QT Interval Prolongation

  • The studies identify several risk factors for QT interval prolongation, including:
    • Female sex 3, 5
    • Advanced age 3, 5, 6
    • Cardiac disease 3, 6
    • Electrolyte abnormalities 3, 7
    • Exposure to certain drugs, such as antiarrhythmic drugs, antibiotics, and antipsychotics 3, 4, 5, 7
  • These risk factors can increase the likelihood of developing a prolonged QT interval and subsequently TdP 3, 4, 5, 6, 7.

Clinical Management of QT Interval Prolongation

  • The studies emphasize the importance of careful prescribing of QT-prolonging drugs, including an individualized assessment of risks and benefits before use, performing baseline and periodic electrocardiograms and measurement of electrolytes, especially during acute illnesses 3, 5, 7.
  • Clinicians should be aware of the potential for drug interactions that can increase the risk of QT interval prolongation and TdP 3, 4, 5, 7.
  • The development of a simple algorithm to guide clinical management in patients who are at risk of QT prolongation/TdP can help support clinicians in their daily practice 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Managing drug-induced QT prolongation in clinical practice.

Postgraduate medical journal, 2021

Research

Pharmacological treatment of acquired QT prolongation and torsades de pointes.

British journal of clinical pharmacology, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.